Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VELOCITY-Lung: Novel Treatment Combinations in Lung Cancer
NCT05633667Phase 2Active, not recruiting
- Sponsor
- Gilead Sciences
- Start
- Mar 2023
- Primary completion
- Sep 2029
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 8
01
Overview
A Phase 2 trial of zimberelimab, domvanalimab, sacituzumab govitecan, etrumadenant in non-small cell lung cancer (NSCLC), sponsored by Gilead Sciences. Started Mar 2023; status: active, not recruiting.
02
Drugs
zimberelimabdomvanalimabsacituzumab govitecanetrumadenant
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05633667.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05633667.